Content deleted Content added
No edit summary |
|||
(31 intermediate revisions by 19 users not shown) | |||
Line 1:
{{Short description|Psychedelic tryptamine}}
{{Drugbox
| drug_name = 5-Methoxy-''N'',''N''-diisopropyltryptamine
Line 13 ⟶ 12:
<!--Clinical data-->
| tradename =
| legal_BR = F2
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-07-24 |title=RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |url-status=live |archive-url=https://web.archive.org/web/20230827163149/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451 |archive-date=2023-08-27 |access-date=2023-08-27 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-07-25}}</ref>
| legal_UK = Class A
| legal_US = Schedule I
Line 27 ⟶ 28:
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01441
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C22724
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 133247
Line 44 ⟶ 47:
}}
[[Image:5meodipt.jpg|thumb|right|5-MeO-DiPT tablets from [[Salem, Oregon|Salem]], [[Oregon]]]]
'''5-Methoxy-''N'',''N''-diisopropyltryptamine''' ('''5-MeO-DiPT''', sometimes called '''
==Pharmacology==
The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[agonist|agonism]], although additional mechanisms of action such as [[monoamine oxidase inhibitor|monoamine oxidase inhibition]] (MAOI) may be involved also.<ref name="pmid17223101">{{cite journal | vauthors = Nagai F, Nonaka R, Satoh Hisashi Kamimura K | title = The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | journal = European Journal of Pharmacology | volume = 559 | issue = 2–3 | pages =
5-MeO-DiPT is [[Neurotoxin|neurotoxic]] in rats.<ref>{{
==Overdose==
Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. A number of these overdoses are attributed to the drug’s extended onset of action, where first time users, who were unfamiliar with the drug, administered a second dose after initially feeling no effects. [[Rhabdomyolysis]] and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.<ref>{{cite book |
==Drug prohibition laws==
Line 82 ⟶ 85:
On April 4, 2003, the [[United States]] [[Drug Enforcement Administration|DEA]] added both 5-MeO-DiPT and [[Alpha-Methyltryptamine|alpha-methyltryptamine]] (AMT) to Schedule I of the [[Controlled Substances Act]] under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004. Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues such as [[Diisopropyltryptamine|DiPT]], and [[Dipropyltryptamine|DPT]], neither of which have yet been expressly outlawed.
== See also ==
* [[5-MeO-DiBF]]
* [[5-MeO-DMT]]
Line 94 ⟶ 97:
* [[N-Methyl-N-isopropyltryptamine|MIPT]]
== References ==
{{Reflist}}
== External links ==
* [http://www.deadiversion.usdoj.gov/fed_regs/rules/2004/fr0929.htm Official Ruling Placing 5-MeO-DIPT into Schedule I]
* [http://www.erowid.org/chemicals/5meo_dipt/5meo_dipt.shtml Erowid information on 5-MeO-DIPT].
Line 114 ⟶ 117:
[[Category:Neurotoxins]]
[[Category:Diisopropylamino compounds]]
[[Category:Methoxy compounds]]
|